90
Participants
Start Date
May 17, 2017
Primary Completion Date
November 9, 2018
Study Completion Date
July 19, 2019
Brivanib 800 mg, QD
Brivanib Alaninate 800 mg QD, PO
Brivanib 400 mg, BID
Brivanib Alaninate 400 mg BID, PO
Anhui Provincial Hospital, Hefei
Nanfang Hospital, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Harbin Medical University Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Hunan Cancer Hospital, Changsha
China PLA 81st hospital, Nanjing
The first Hospital of Jilin University, Changchun
Army General Hospital of Shenyang military region, Shenyang
Fudan University Shanghai Cancer Center, Shanghai
Zhongshan Hospital, Shanghai
Tangdu Hospital, Xi’an
West China Hospital West China School of Medicine Sichuan University, Chengdu
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY